The tumour microenvironment is not passive scaffolding. It is a dynamic ecosystem made up of cancer cells, fibroblasts, blood vessels, immune cells, extracellular matrix and signalling molecules. These components exchange chemical messages that can influence tumour growth, invasion, treatment resistance and immune suppression. B7-H3 is a membrane-associated protein belonging to the B7 family, a group of molecules involved in communication between immune and non-immune cells. Although its precise receptor interactions and full biological role remain incompletely resolved, B7-H3 has repeatedly been associated with aggressive tumour behaviour, poor clinical outcomes and mechanisms that restrict effective anti-tumour immunity. The review’s central contribution is to examine B7-H3 beyond the cancer cell itself, asking where the molecule is found throughout the tumour ecosystem and what that location could mean biologically.

The authors gathered and assessed published evidence describing B7-H3 expression in tumour-associated stromal cells, vascular structures and immune populations. This type of systematic review is especially important in a field where studies often use different antibodies, staining platforms, scoring systems, tissue samples and disease classifications. In many investigations, B7-H3 is measured by immunohistochemistry, a technique that uses antibodies to identify proteins in preserved tissue sections. Other studies rely on RNA sequencing, transcriptomic databases, flow cytometry or single-cell analyses. These approaches do not always produce directly comparable results. Protein abundance, messenger RNA levels and cellular localisation can tell different stories, and a signal detected in a tumour sample may originate from malignant cells, fibroblasts, endothelial cells or infiltrating leukocytes.

The stromal compartment emerged as a major area of interest because cancer-associated fibroblasts can reshape the physical and chemical environment around a tumour. These fibroblasts produce collagen-rich extracellular matrix, growth factors and inflammatory mediators that may create barriers to immune-cell penetration while supporting tumour expansion. If B7-H3 is present on stromal populations, it could contribute to an immunologically hostile environment in which cancer-fighting T cells are excluded, weakened or functionally reprogrammed. The review does not reduce this biology to a single universal mechanism; instead, it presents a landscape in which B7-H3 expression varies according to tumour type, cellular identity and experimental method. That variability may be crucial for determining which patients could benefit from therapies designed to recognise or block the protein.

Blood vessels represent another potentially important B7-H3-rich territory. Tumour-associated vessels are often structurally abnormal, leaky and poorly organised, producing uneven oxygen delivery and impairing the movement of immune cells into malignant tissue. Endothelial cells lining these vessels regulate which cells can leave the bloodstream and enter the tumour. The presence of B7-H3 in vascular structures could therefore have implications far beyond a simple diagnostic stain. It may be connected to endothelial activation, abnormal angiogenesis or the selective recruitment and retention of immune populations. In practical terms, vascular B7-H3 could offer therapeutic access: an antibody, antibody-drug conjugate or engineered immune cell that reaches the tumour through the circulation might encounter the target on both malignant and vascular-associated cells.

The immune landscape described in the literature is equally complex. B7-H3 has been reported in association with several immune-cell populations, but its functional significance may depend on the tissue context and the state of cellular activation. Tumour-infiltrating lymphocytes, macrophages, dendritic cells and other leukocytes can adopt different phenotypes in response to local signals. A molecule that appears on an immune cell may reflect activation, suppression, differentiation or a feedback response to chronic inflammation. Because B7-H3 biology does not fit neatly into the best-known immune checkpoints, its effects are still being investigated. The protein may influence T-cell activity, cytokine networks and the balance between immune surveillance and tolerance, but the review underscores that expression alone cannot prove a direct functional effect.

That distinction is central to interpreting the findings. Detecting B7-H3 in a particular cell type does not automatically demonstrate that the molecule is driving tumour progression. A protein can be abundant without being essential, or it can be present only during a specific stage of disease. Its impact may also depend on whether it is located on the cell surface, stored inside the cell, released in a soluble form or concentrated at points of contact between neighbouring cells. In addition, different tumour types may use B7-H3 in different ways. A signal associated with immune suppression in one cancer could reflect vascular remodelling or stromal activation in another. By collecting evidence across compartments, the review helps expose these distinctions rather than treating B7-H3 as a uniform marker.

The findings have direct relevance for the rapidly expanding field of B7-H3-directed therapeutics. Several strategies are being explored in cancer research, including monoclonal antibodies, antibody-drug conjugates, bispecific molecules and chimeric antigen receptor T cells. Each approach depends on a detailed understanding of where the target is located. An antibody-drug conjugate may exploit B7-H3 on tumour cells to deliver a toxic payload, while a bispecific therapy could bring immune cells into contact with B7-H3-positive targets. CAR-T cells require careful assessment of target density, tissue distribution and the risk of attacking healthy organs. If B7-H3 is present in stromal or vascular compartments, therapies may affect the tumour’s supporting infrastructure as well as the malignant cells, potentially improving penetration and weakening resistance but also increasing the need for safety monitoring.

The review also points to a major challenge in translating B7-H3 research into clinical practice: the field needs more consistent measurements and better spatial information. Conventional pathology can identify whether a tissue sample contains B7-H3, but advanced technologies can show precisely which cells express it, how strongly they express it and how those cells are positioned relative to blood vessels or immune infiltrates. Multiplex immunofluorescence, spatial transcriptomics and single-cell sequencing could help distinguish overlapping signals that conventional staining cannot resolve. Future studies will also need to connect these maps with patient outcomes, treatment responses and adverse events. A target becomes clinically useful not merely when it is common, but when its presence predicts vulnerability to a specific intervention or identifies a biologically meaningful patient group.

For now, the systematic review places B7-H3 within a broader and more realistic picture of cancer biology. The protein is not simply a marker decorating tumour cells; it may be part of a distributed network involving the malignant compartment, the connective tissue that surrounds it, the vessels that feed it and the immune cells that attempt to control it. That network could explain why B7-H3-directed therapies are generating interest across multiple tumour types, while also warning against one-size-fits-all assumptions. By mapping where B7-H3 appears in the tumour microenvironment, Privitera and colleagues provide a framework for designing more precise experiments and more selective treatments. The next phase of research will determine whether this molecular map can be converted into measurable clinical benefit for patients whose cancers exploit the protein’s many locations.

Subject of Research: B7-H3 expression in the tumour microenvironment, including stromal, vascular and immune compartments.

Article Title: Mapping B7-H3 in the tumour microenvironment: a systematic review of stromal, vascular and immune expression.

Article References: Privitera, L., Alberti, P., Senica, S.O. et al. Mapping B7-H3 in the tumour microenvironment: a systematic review of stromal, vascular and immune expression. Br J Cancer (2026). https://doi.org/10.1038/s41416-026-03573-0

Image Credits: AI Generated

DOI: https://doi.org/10.1038/s41416-026-03573-0

Keywords: B7-H3, CD276, tumour microenvironment, cancer immunology, stromal cells, tumour vasculature, immune cells, immune checkpoint, immunotherapy, systematic review

In recent years, the integration of single-cell omics technologies has catalyzed a paradigm shift in our understanding of tumor biology. This approach allows for an unprecedented examination of the heterogeneity present within tumors, especially in the context of metastatic spread. Liu and colleagues utilized single-cell RNA sequencing and other omics techniques to dissect the complex cellular ecosystems within lymph nodes affected by metastatic tumors. This meticulous analysis reveals not just the cellular constituents but also their functional states and signaling pathways active during the cancer progression process.

The implications of their findings cannot be overstated, as they provide crucial insights into how tumor cells communicate with their microenvironment. The study emphasizes the role of immune checkpoint molecules and growth factors in dictating the fate of both tumor and immune cells located in lymph nodes. By understanding these molecular interactions, researchers can devise strategies to manipulate these pathways, potentially preventing or slowing down the spread of cancer to lymphatic tissues.

Moreover, the identification of key signaling pathways involved in lymph node metastasis opens up new avenues for therapeutic interventions. For instance, specific inhibitors targeting the signaling pathways that promote metastasis could be developed, thereby impeding the ability of tumor cells to disseminate. Liu et al. detail how these strategies can be tailored to challenge the unique molecular fingerprints observed in different cancers, providing a personalized approach to treatment.

Another critical aspect highlighted in the research is the role of the tumor microenvironment in supporting metastatic processes. The complexity of cellular interactions among tumor cells, immune cells, and stromal components serves as a rich ground for the development of metastasis. By utilizing single-cell transcriptomics, Liu and colleagues were able to profile the diverse populations of cells within sentinel lymph nodes, illuminating the ways in which tumor cells adapt and thrive in this niche.

Furthermore, the study sheds light on how systemic factors such as cytokines and hormones participate in modulating the metastatic potential of tumor cells. Liu et al. demonstrate that these factors can either suppress or enhance metastasis depending on the context, indicating a delicate balance that must be understood when devising therapeutic strategies. This insight provides a rationale for considering systemic therapies that might work synergistically with local treatments aimed at eradicating tumors.

The research also draws attention to the evolving paradigm of cancer treatment, which increasingly emphasizes the need for combination therapies. By integrating immunotherapy, targeted therapy, and possibly even gene therapy into a consolidated treatment strategy, there is hope to significantly impact the metastasis rate, particularly in cases where lymph nodes become involved. Liu and colleagues propose that single-cell omics could be critical in identifying which combinations of therapies might yield the best results for specific patient populations.

In light of these findings, the potential for development of biomarkers based on single-cell analyses becomes apparent. Liu et al. discuss the possibility of identifying specific cellular signatures that predict the likelihood of metastasis in patients. This could allow clinicians to tailor surveillance strategies and treatment plans according to the metastatic risk profiles, ultimately leading to better management of cancer patients.

As the field of cancer research continues to evolve, the importance of interdisciplinary collaboration between oncologists, molecular biologists, and bioinformaticians cannot be understated. The insights garnered from single-cell omics studies like those conducted by Liu and his team underscore the necessity of integrating diverse expertise to unravel the complexities of cancer metastasis. By adopting a more holistic perspective, cancer research can advance toward more effective prevention and treatment strategies.

The momentum generated by this research is likely to accelerate the deployment of advanced therapeutics that target specific cellular pathways implicated in lymph node metastasis. As more studies confirm and expand upon Liu et al.’s findings, we can expect to see a rich tapestry of innovative treatment options emerging, tailored to the unique molecular characteristics of patients’ tumors.

In summary, Liu et al.’s comprehensive investigation into lymph node metastasis, utilizing cutting-edge single-cell omics technology, marks a significant milestone in our understanding of cancer biology. The potential to influence therapeutic approaches derived from these insights paints a hopeful picture for the future of cancer treatment.

As researchers continue to elucidate the intricate web of factors contributing to lymph node metastasis, the overarching goal remains clear: to find effective ways to halt the progression of cancer and improve survival rates for patients worldwide. The collective effort of the scientific community, inspired by studies like those conducted by Liu and his colleagues, is pivotal in driving this change forward.

In conclusion, the groundbreaking work by Liu et al. not only contributes to the profound understanding of tumor lymphatic metastasis but also heralds a new era of precision medicine, where therapies can be stratified based on the unique biological characteristics of a patient’s tumor. This convergence of technology and biology is set to alter the landscape of cancer treatment forever.

Subject of Research: Single-cell omics in tumor lymph node metastasis

Article Title: Single-cell omics in tumor lymph node metastasis: mechanisms and therapeutic implications

Article References:

Liu, X., Meng, X., Liu, Z. et al. Single-cell omics in tumor lymph node metastasis: mechanisms and therapeutic implications.
Mol Cancer (2026). https://doi.org/10.1186/s12943-026-02585-x

Image Credits: AI Generated

DOI: 10.1186/s12943-026-02585-x

Keywords: tumor metastasis, lymph nodes, single-cell omics, cancer biology, therapeutic implications, immune cells, signaling pathways, precision medicine.

SIGLEC15 is a transmembrane protein that has recently garnered attention for its immunosuppressive capabilities across diverse solid tumor types, including breast cancer. Despite its relatively nascent characterization, accumulating evidence suggests that SIGLEC15 functions as a pivotal immune checkpoint molecule, distinct from the classical PD-1/PD-L1 axis, and may orchestrate tumor immune evasion by modulating myeloid cells and T-cell activity. Given these insights, a comprehensive elucidation of SIGLEC15’s role in breast cancer biology could unveil novel avenues for therapeutic intervention and biomarker-driven treatment stratification.

A team of investigators from Chongqing Medical University undertook an integrative study employing multi-omics datasets—namely TCGA (The Cancer Genome Atlas), GTEx (Genotype-Tissue Expression), and GEO (Gene Expression Omnibus)—to dissect the clinical and molecular significance of SIGLEC15 in breast cancer. Their analyses revealed a paradoxical yet intriguing association: elevated SIGLEC15 expression correlated with improved overall survival and favorable five-year prognosis. This counterintuitive finding challenges the conventional notion of immune checkpoints merely facilitating tumor progression, suggesting a complex and context-dependent functional spectrum for SIGLEC15 within the tumor milieu.

Delving deeper through single-cell RNA sequencing (scRNA-seq) of breast cancer tissue samples, the researchers pinpointed SIGLEC15 expression predominantly in malignant epithelial cells. These SIGLEC15-positive populations were characterized by a notable reduction in infiltrating CD4⁺ and CD8⁺ T-lymphocytes along with diminished presence of M0 and M1 macrophage subsets. Conversely, there was an enrichment of dendritic cells and B cells, indicative of a shift toward humoral immune mechanisms and an immunosuppressive microenvironment less conducive to cytotoxic T-cell mediated tumor eradication. This immune landscape remodeling underscores SIGLEC15’s role in shaping cellular cross-talk within the TME to favor immune escape.

Beyond its immunomodulatory effects, SIGLEC15 emerged as a critical regulator of epithelial–mesenchymal transition (EMT), a key driver of tumor invasiveness and metastasis. Functional assays demonstrated that SIGLEC15 exerts suppressive control over EMT by downregulating ZEB1, a master transcriptional regulator of this process. Overexpression models in the aggressive breast cancer cell lines BT549 and MDA-MB-231 revealed marked decreases in ZEB1 protein levels alongside classical mesenchymal markers such as N-cadherin and vimentin. Correspondingly, these alterations translated into diminished migratory and invasive capabilities as evidenced by wound healing assays and transwell migration metrics.

Conversely, silencing SIGLEC15 in MDA-MB-231 cells elicited robust enhancement in EMT phenotypes, underpinning its tumor suppressor-like function with respect to metastatic potential. These reciprocal functional validations underscore SIGLEC15’s dualistic role, whereby it modulates both immune suppression and tumor cell plasticity — a nuanced interplay that challenges prevailing assumptions and invites reconsideration of its utility as a therapeutic target.

Importantly, their investigation extended to therapeutic vulnerability profiling, revealing that high SIGLEC15-expressing breast tumors exhibited lower sensitivity to conventional platinum-based chemotherapies and PARP inhibitors, agents typically efficacious in DNA damage response deficient malignancies. Intriguingly, these same tumors demonstrated pronounced susceptibility to Nutlin-3a, a small-molecule antagonist of MDM2 that stabilizes and activates p53 tumor suppressor pathways. This finding suggests that SIGLEC15 expression status might serve as a predictive biomarker for tailoring treatment regimens, prioritizing MDM2 inhibition in tumors less amenable to DNA-damaging agents.

In vivo xenograft studies corroborated these insights, with Nutlin-3a markedly suppressing tumor growth in SIGLEC15-overexpressing models while low-SIGLEC15 tumors were more responsive to carboplatin chemotherapy. This mechanistic synergy between SIGLEC15 expression and drug response highlights the potential for integrating molecular diagnostics into therapeutic decision-making, advancing the paradigm of personalized medicine in breast cancer care.

Collectively, this comprehensive work delineates SIGLEC15 as a multifaceted mediator within the breast cancer TME that simultaneously modulates immune architecture and tumor cell invasive behavior. Its dual capacity to suppress EMT and orchestrate an immunosuppressive microenvironment positions it uniquely at the crossroads of tumor progression and immune evasion, rendering it a compelling candidate for translational research and clinical exploitation.

The implications are profound: beyond serving as a prognostic biomarker, SIGLEC15 may guide therapeutic selection—steering patients toward MDM2 inhibitors when overexpressed, while identifying those poised to benefit from platinum-based regimens in its absence. Furthermore, targeting SIGLEC15 or its downstream pathways could potentiate novel immunotherapeutic strategies that circumvent immune checkpoint resistance and metastasis.

This study exemplifies the power of integrating genomic, transcriptomic, and functional data to unravel complex tumor biology and paves the way for future clinical trials assessing SIGLEC15-targeted approaches. As breast cancer treatment pivots toward increasingly sophisticated and individualized paradigms, deciphering the molecular underpinnings of players like SIGLEC15 will be indispensable in improving patient outcomes and quality of life.

Subject of Research: Breast cancer; tumor microenvironment; SIGLEC15; immunosuppression; epithelial–mesenchymal transition

Article Title: SIGLEC15 modulates the immunosuppressive microenvironment and suppresses malignant phenotypes in triple-negative breast cancer

Web References:
https://www.sciencedirect.com/journal/genes-and-diseases
http://dx.doi.org/10.1016/j.gendis.2025.101799

References:
ZhaoFu Tan, Hongbin Xin, Jian Chen, Ming Lei, Gang Tu, Lingfeng Tang. SIGLEC15 modulates the immunosuppressive microenvironment and suppresses malignant phenotypes in triple-negative breast cancer. Genes & Diseases. DOI: 10.1016/j.gendis.2025.101799

Image Credits: ZhaoFu Tan, Hongbin Xin, Jian Chen, Ming Lei, Gang Tu, Lingfeng Tang

Keywords: Breast cancer, SIGLEC15, tumor microenvironment, immunosuppression, epithelial–mesenchymal transition, MDM2 inhibitor, Nutlin-3a, chemoresistance, single-cell RNA sequencing, prognostic biomarker

The findings indicate that VISTA functions as an immune checkpoint molecule, which modulates the activity of immune cells in the tumor microenvironment. This modulation is facilitated by the regulation of m6A, a common RNA modification that influences gene expression and stability. Research has demonstrated that altered m6A methylation patterns can lead to significant differences in the expression of immune checkpoints like VISTA. The implications of this regulatory mechanism are profound, particularly in a disease as aggressive as NSCLC, where immune evasion is a critical characteristic of tumor growth and metastasis.

At the heart of the study is the intricate interplay between m6A methylation, VISTA expression, and the immune response orchestrated by STAT3 signaling pathways. The researchers identified that the activation of STAT3 was critical for the expression of CCL22, a chemokine that recruits and activates regulatory T cells (Tregs). Tregs play a crucial role in dampening the immune response against tumors, thus promoting an environment conducive to cancer progression. By elucidating these pathways, the researchers provide a clearer understanding of how tumors can manipulate immune responses to their advantage.

As NSCLC remains a leading cause of cancer-related mortality worldwide, the identification of VISTA as a modulator of immune responses highlights a potential target for immunotherapy. Therapies aimed at inhibiting VISTA could have significant implications for enhancing the effectiveness of existing treatments, such as checkpoint inhibitors that target PD-1/PD-L1 pathways. The ability to harness the intrinsic capabilities of the immune system to combat cancer is a cornerstone of modern oncology, and this discovery adds a new dimension to that pursuit.

Moreover, the study contributes to the ever-expanding field of epitranscriptomics, focusing on how RNA modifications influence cellular functions in health and disease. The implications of m6A modification extend beyond NSCLC, potentially impacting various malignancies and other diseases. Understanding the broader consequences of m6A methylation and its interplay with immune modulation could lead to the development of novel strategies aimed at reprogramming immune responses to combat a variety of cancers effectively.

The research also sparks critical discussions regarding the functional implications of tumor-immune interactions. It raises questions about the nature of immune cell infiltration in tumors expressing VISTA and how this expression correlates with clinical outcomes in NSCLC patients. The findings suggest that assessing VISTA levels alongside other immune checkpoints could offer insights into patient prognosis and treatment responses, paving the way for more personalized approaches to cancer therapy.

Furthermore, the investigation into the role of CCL22 in the context of NSCLC adds another layer of complexity to our understanding of tumor-immune dynamics. The ability of tumors to induce Treg accumulation through chemokines like CCL22 highlights the strategic maneuvers employed by cancer cells to escape immune detection. It beckons further exploration into the mechanisms behind Treg recruitment and the functional consequences of their presence within the tumor microenvironment, which could potentially inform future therapeutic targets.

As the study by Xu, Shen, and Jiang gains traction within the scientific community, it is likely to attract attention not only for its immediate findings but also for its overarching implications in cancer biology. The prospect of targeting VISTA and its regulatory pathways presents a tantalizing opportunity for researchers and clinicians alike. It accentuates the need for more comprehensive studies that can validate these findings in larger cohorts and different cancer types.

In conclusion, the research uncovering the role of VISTA expressed on tumor cells as a mediator of immune responses in NSCLC marks a significant advancement in the field of cancer immunology. As scientists continue to unravel the complexities of tumor-intrinsic mechanisms that facilitate immune evasion, the potential for novel therapeutic strategies expands. The integration of these findings into clinical oncology may hold the key to transforming the landscape of cancer treatment, with the hope of enhancing patient outcomes and survival rates in the battle against this devastating disease.

In an era of rapid advancements in cancer research, every discovery builds upon previous knowledge, leading to new horizons in treatment strategies. The interplay between RNA modifications like m6A, immune checkpoints such as VISTA, and the broader immune landscape underscores the complexity of the tumor microenvironment and the multifaceted approaches necessary to tackle cancer effectively. These findings not only inform ongoing research but also inspire optimism for developing innovative therapies that harness the immune system’s full potential.

The study underscores the importance of continued exploration into the regulatory mechanisms that govern immune system interactions with tumors. As researchers delve deeper into the nuances of these pathways, we may witness the emergence of new modalities that could redefine the standard of care for lung cancer patients and potentially those afflicted by other malignancies.

The evolving narrative around cancer therapy is one of collaboration, with diverse disciplines coming together to shed light on the intricacies of tumor biology. The insights gleaned from this research are crucial for driving forward the next generation of immunotherapies and biomarker development, signaling a brighter future for patients combating the realities of non-small cell lung cancer.

The implications of this research extend beyond the laboratory, offering a promise of hope to the thousands of patients battling this formidable disease. By understanding how tumors manipulate their microenvironment, researchers can better strategize and develop tailored therapies that can outsmart the cunning adaptations of cancer cells. The pursuit of innovative treatments based on this foundational research could lead to transformative changes in the treatment landscape for NSCLC.

In summary, the incisive work by Xu, Shen, Jiang, and their colleagues illuminates pathways previously shrouded in mystery within NSCLC. This is not merely an academic inquiry; it is a clarion call for further investigation into immune modulation in cancer, urging the scientific community to unite in a multifaceted approach to conquer the challenges posed by this disease. The findings serve as a beacon, guiding future research and fostering hope for improved therapeutic strategies that can ultimately save lives.

Subject of Research: The role of VISTA expressed on tumor cells in regulating the immune microenvironment in non-small cell lung cancer (NSCLC).

Article Title: VISTA expressed on tumor cells is regulated by m6A and influences immune microenvironment through STAT3/CCL22 in NSCLC.

Article References:

Xu, H., Shen, K., Jiang, B. et al. VISTA expressed on tumor cells is regulated by m6A and influences immune microenvironment through STAT3/CCL22 in NSCLC.
J Transl Med 23, 1043 (2025). https://doi.org/10.1186/s12967-025-06818-3

Image Credits: AI Generated

DOI:

Keywords: VISTA, m6A, immune microenvironment, non-small cell lung cancer, STAT3, CCL22, tumor immunology, immunotherapy.